Felipe Furiati

In the pharma and biopharma sector, where even the smallest delay can have life-or-death consequences, effective supply chain management is essential to delivering vital medicines on time and at scale.

Today’s global supply chains are more complex than ever, shaped by geopolitical instability, tariffs, fragile material supplies, and the specialised requirements of modern therapies. The impact is clear: pharma companies face mounting delays and rising costs, while CMOs must navigate increasing operational challenges.

This session will explore how pharma and CMOs can manage supply chain disruptions by moving beyond a traditional “buyer–vendor” relationship toward a shared-risk, shared-reward partnership built on transparency, joint planning and co-investment.

Key discussion points include:

• Joint risk management & transparency: Mapping supply chains collaboratively and sharing data on potential risks.
• Collaborating on quality: Standardising audits and processes to reduce duplication and streamline compliance.
• Adopting new technologies: Partnering on pilot programs for advanced manufacturing and supply chain innovation.